SYNTHESIS, IN VITRO AND IN VIVO ACTIVITY OF NOVEL 9-DEOXO-9a-AZA-9a-HOMOERYTHROMYCIN A DERIVATIVES; A NEW CLASS OF MACROLIDE ANTIBIOTICS, THE AZALIDES

A series of erythromycin A-derived semisynthetic antibiotics, featuring incorporation of a basic nitrogen atom into a ring expanded (15-membered) macrocyclic lactone, have been prepared and biologically evaluated. Semisynthetic modifications focused upon (1) varied substitution at the macrocyclic ri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antibiotics 1988/08/25, Vol.41(8), pp.1029-1047
Hauptverfasser: BRIGHT, G. MICHAEL, NAGEL, ARTHUR A., BORDNER, JON, DESAI, KISHOR A., DIBRINO, JOSEPH N., NOWAKOWSKA, JOLANTA, VINCENT, LAWRENCE, WATROUS, RICHARD M., SCIAVOLINO, FRANK C., ENGLISH, ARTHUR R., RETSEMA, JAMES A., ANDERSON, MARGARET R., BRENNAN, LORI A., BOROVOY, ROBERTA J., CIMOCHOWSKI, CAROLINE R., FAIELLA, JAMES A., GIRARD, ARTHUR E., GIRARD, DENNIS, HERBERT, CAROL, MANOUSOS, MARY, MASON, RACHEL
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of erythromycin A-derived semisynthetic antibiotics, featuring incorporation of a basic nitrogen atom into a ring expanded (15-membered) macrocyclic lactone, have been prepared and biologically evaluated. Semisynthetic modifications focused upon (1) varied substitution at the macrocyclic ring nitrogen and (2) epimerization or amine substitution at the C-4" hydroxyl site within the cladinose sugar. In general, the new azalides exhibit improved Gram-negative potency, expanding the spectrum of erythromycin A to fully include Haemophilus influenzae and Neisseria gonorrhoeae. When compared to erythromycin A, the azalides exhibit substantially increased half-life and area-under-the-curve values in all species studied. The overall in vitro/in vitro performance of N-methyl, C-4" epimers 3a and 9; and C-4" amine 11 identify these compounds as the most interesting erythromycin A-superior agents. Compound 3a has been advanced to clinical study.
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.41.1029